Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

16.80 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Globant, Doximity, Applied Materials And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Via Benzinga
IBD 50 Stock Travere Therapeutics Nosedived On An FDA Decision — Here's Why
Analysts are still bullish on the company's chances of being the first to win approval for an FSGS drug. 
Via Investor's Business Daily
Topics Government
Exposures Political Product Safety
Top movers in Friday's pre-market session
As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Earnings Scheduled For May 1, 2025
Via Benzinga
Travere Therapeutics's Earnings: A Preview
Via Benzinga
Analyst Expectations For Travere Therapeutics's Future
Via Benzinga
Why Quantum Computing Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Travere Stock Nosedives As FDA Schedules Advisory Meeting For Kidney Drug's Supplemental Use: Retail Shrugs Off Worries
Under the Prescription Drug User Fee Act, the agency has now set a target action date of Jan. 13, 2026. 
Via Stocktwits
Exposures Product Safety
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Thursday's after hours session: top gainers and losers
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Earnings Scheduled For February 20, 2025
Via Benzinga
A Preview Of Travere Therapeutics's Earnings
Via Benzinga
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
Via Benzinga
Is TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) following the Minervini trend for explosive growth?
Should you consider TRAVERE THERAPEUTICS INC (NASDAQ:TVTX) for high growth investing? A fundamental and technical analysis of (NASDAQ:TVTX). 
Via Chartmill
Assessing Travere Therapeutics: Insights From 8 Financial Analysts
Via Benzinga
Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval
The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage. 
Via Investor's Business Daily
Exposures Product Safety
The Analyst Verdict: Travere Therapeutics In The Eyes Of 7 Experts
Via Benzinga
Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
Via Benzinga
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Via Benzinga
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Travere Therapeutics Sparks Retail Frenzy As Stock Hits Over 2-Year High On FDA Approval Plan For Kidney-Disease Drug
The company expects to submit a supplemental New Drug Application (sNDA) based on existing Phase 3 and Phase 2 data by the end of the first quarter. 
Via Stocktwits
Exposures Product Safety
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease Drug
The company is nearing a highly anticipated approval for a kidney disease drug. 
Via Investor's Business Daily
Exposures Product Safety
Lattice Semiconductor, SelectQuote, Radiant Logistics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
Exposures Artificial Intelligence Political
3 Under-the-Radar Healthcare Companies
While established healthcare firms are among the most stable stocks in the sector, up-and-coming companies can offer the potential for greater gains. 
Via MarketBeat
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
Jim Cramer warns Travere Therapeutics is losing a ton of money. He advises holding onto Palantir as a spec and expects good news from Stanley Black & Decker. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Travere Therapeutics Hits 14-Month High On A Promising FDA 'Pivot' In Kidney Disease
The company could soon ask for approval of its only drug, Filspari, in a second disease. 
Via Investor's Business Daily
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.